- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155752
Pulmozyme in Cystic Fibrosis With Sinusitis
Z4770s, Use of Recombinant Human DNASE in Cystic Fibrosis Patients With Chronic Sinusitis to Prevent Acute Sinusitis Exacerbations and Improve Symptoms and Outcomes - A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be a prospective enrollment of patients with CF and rhinosinusitis in a double-blind crossover study with nasal nebulized DNASE versus saline. Nebulization will be accomplished with PARI SinuStar nasal aerosol system nebulizer set powered by an air compressor. This will be a pilot study with each subject serving as their own control. Each arm of the study will be 3 months and randomization to active drug versus placebo will be generated without the knowledge of subject or researchers. A health care provider not involved in the care of the subject will be responsible for medication distribution and the randomization scheme. A daily diary will collect data for analysis. Visits will be arranged every 4 weeks at which time drug will be dispensed, adherence to daily diary and compliance to medication will be assessed. At each visit the SF-12, SNOT-20, Epworth Sleepiness Scale, Rhinitis Severity Scale, Nocturnal Rhinoconjunctivitis Quality of Life Specific Questionnaire (NRQLQ), Cystic Fibrosis Questionnaire-Revised, and Rhinosinusitis Quality of Life Survey will be utilized for acquisition of data (17-23). In addition, a Physician Global Assessment and a self administered patient rhinosinusitis VAS score (0-100 with 100 full recovery and 0 no effect) will be completed at each visit. To obtain objective data patients will have nasal endoscopic assessment at 4 different time points and nasal polyps and sinusitis rated on a scale as defined by Lund and Kennedy in the Ann Otol Laryngol 1995;104 (suppl 167):17-21. (24) Serial sinus CT scans will be avoided to decrease irradiation risk.
Subjects: A total of 12 patients will be enrolled in this pilot study, and recruitment will be through the Cystic Fibrosis Center at Penn State University, after IRB approval. All subjects must be over the age of 15 years (the age the investigators consider to be necessary to understand the consent and questionnaires required for the study), be of either gender and of any ethnicity. Subjects will be able to continue all presently used nasal and respiratory medications as long as the present therapeutic regimen has been used for one month prior to enrollment and these therapies have been used at a stable dose, method of distribution and without adverse events
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Unicersity
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with CF, age >15yo
- Chronic sinusitis with symptoms
- VAS score of at least 60 (0 to 100) reflecting symptoms associated with rhinosinusitis
- CT scan demonstrating non-complicated sinusitis (defined as rhinosinusitis without orbit perforation, osteomyelitis, peri-sinus cellulitis, or meningitis)
Exclusion Criteria:
- No evidence of sinusitis
- VAS score for rhinosinusitis less than 60 on a scale of 0 to 100
- Complicated sinusitis (defined as orbit perforation, osteomyelitis, peri-sinus cellulitis, meningitis complicating sinusitis)
- Prior adverse events or allergy to DNASE
- Unwilling to sign an approved IRB consent
- Immediate indication for sinus surgery
- Inability to adhere to therapy and understand and to complete questionnaires.
- Being pregnant will exclude a subject from participating and the subjects will be requested to take birth control methods if actively engaging in sex. Further more, subjects will be requested to inform the investigators if they become pregnant. Pregnancy test will be performed at screening.
- Active nursing of an infant will be an exclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PULMOZYME
active drug
|
• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl.
The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
Other Names:
|
Placebo Comparator: placebo
cross over to placebo
|
identical placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. To assess changes in quality of life of patients with Cystic Fibrosis while on DNASE as compared to placebo.
Time Frame: weeks
|
Sinusitis will be a significant burden for patients with CF.
Use of nasal nebulized recombinant human DNASE will demonstrate positive changes in symptoms of rhinosinusitis and will improve the quality of life of patients with Cystic Fibrosis.
In addition, subjects on active therapy will have a decrease in acute infections and a decrease in disease burden as compared to when the subject is on placebo therapy.
|
weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy Craig, DO, Penn State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Pancreatic Diseases
- Fibrosis
- Sinusitis
- Cystic Fibrosis
Other Study ID Numbers
- IRB#33344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
St. Louis UniversityTerminatedStent | Sinusitis, FrontalUnited States
-
Oulu University HospitalTampere University HospitalRecruitingSinusitis | Maxillary Sinusitis | Sinusitis, AcuteFinland
-
Cairo UniversityNot yet recruitingChronic Maxillary Sinusitis
-
Centre Hospitalier Intercommunal CreteilActive, not recruitingChronic Maxillary SinusitisFrance
-
DeyCompletedACUTE SINUSITISUnited States
Clinical Trials on Pulmozyme single use ampule
-
Istituto Clinico HumanitasNot yet recruitingDisease of Gastrointestinal Tract
-
Erasmus Medical CenterAmbu A/S; Maag Lever Darm StichtingCompletedEsophagogastroduodenoscopy | Gastroscopy | Equipment Design | Equipment Contamination / Prevention & Control | Cross Infection / Prevention & Control | Disposable Equipment | Infection Control / MethodsNorway, Netherlands
-
Nottingham University Hospitals NHS TrustCompleted
-
Wellspect HealthCareCompletedUrinary CatheterizationUnited Kingdom, Netherlands, Austria, Germany, Italy, Sweden
-
Peking University Third HospitalBeijing Friendship HospitalCompletedSingle-use Precision Filter Infusion SetChina
-
Procter and GambleCompletedStress Urinary Incontinence (SUI)United States
-
Clinical Hospital Centre ZagrebRecruitingStridor | Atelectasis | HemoptysisCroatia
-
Boston Scientific CorporationCompletedEndoscopic Retrograde CholangiopancreatographyUnited States, France, Hong Kong, Singapore, Australia, Canada, Germany, India, Italy, Netherlands, South Africa
-
Universitätsklinikum Hamburg-EppendorfCompletedRespiratory InsufficiencyGermany
-
St George Hospital, AustraliaCompletedUrinary RetentionAustralia